Mineralys Therapeutics Jensen Alpha
| MLYS Stock | | | 29.35 -0.77 -2.56% |
Jensen Alpha measures the return attributable to active skill rather than passive market exposure. It is the residual return after subtracting the risk-free rate and the beta-adjusted market premium — the return the asset should have earned based solely on its systematic risk. Below is Mineralys Therapeutics's current Jensen Alpha with peer comparisons and related risk metrics.
Current Jensen Alpha Value
Mineralys Therapeutics has a Jensen Alpha of
-0.05, indicating slightly negative alpha — return marginally below the CAPM-predicted level. Mineralys Therapeutics has slightly underperformed relative to what its market beta would imply.
Jensen Alpha | = | ER[a] - RFR * (1-BETA) | - | BETA * ER[b]) |
| = | -0.05 | |
| ER[a] | = | Expected return on investing in Mineralys Therapeutics |
| ER[b] | = | Expected return on market index or selected benchmark |
| BETA | = | Beta coefficient between Mineralys Therapeutics and the market |
| RFR | = | Risk Free Rate of return. Typically T-Bill Rate |
Jensen Alpha Peers Comparison
Relative to peers, Mineralys Therapeutics's Jensen Alpha is below the group average of 0.35. Peer readings range from -0.2838 (Adaptive Biotechnologies Corp) to 1.77 (Cidara Therapeutics), reflecting wide dispersion across the sector. Mineralys Therapeutics has generated less excess return relative to its market exposure than the peer group average.
Jensen Alpha Relative To Other Indicators
The chart below plots Jensen Alpha against Maximum Drawdown for Mineralys Therapeutics and its peers. Each point represents one equity — position along the horizontal axis shows Jensen Alpha while the vertical axis shows Maximum Drawdown. Equities that cluster in different quadrants carry distinct risk-return profiles. Use the dropdowns to swap in other indicators for either axis.
Compare Mineralys Therapeutics to PeersMethodology, Assumptions & Data Sources
Mineralys Therapeutics has a current Jensen Alpha reading of -0.05. The Jensen Alpha for Mineralys Therapeutics is produced by transforming raw price history into a standardized measure according to the indicator's defined methodology. Data sources include daily closing prices from supported exchanges, with standard corporate action adjustments applied. Mineralys Therapeutics operates in the health care sector, which may exhibit distinct volatility and momentum characteristics relative to the broader market. The output reflects the selected calculation window — changing the horizon will produce different readings. This stock metric is provided for analytical reference.
Other Technical Indicators